News | October 12, 2022
Merck recognized on Fortune’s 2022 change the World List
This recognition marks the third time in five years that Merck has been included on Fortune’s Change the World list.
This recognition marks the third time in five years that Merck has been included on Fortune’s Change the World list.
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
Ours is a story of India’s resilient public health system and of everyone working together as team India to battle the pandemic
There are certain foods can influence blood pressure, triglycerides, cholesterol levels and inflammation, all of which are risk factors for heart disease.
‘PathoDetect HPV Detection Test’ detects and discriminates the presence of high-risk HPV strains including 16 and 18 which cause most of the cervical cancers.
The ANDA was filed as 'First to File' submission on NCE-1 date.
Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
The objective of this study is to evaluate the efficacy of ASC22 (Envafolimab) combined with Chidamide on the viral reservoirs of latently infected cells in HIV patients.
Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca's long-acting antibody combination “Evusheld” for the prevention ) and treatment of COVID-19.
iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy
Subscribe To Our Newsletter & Stay Updated
